Yubo International Biotech Reports Decreased Net Loss and Ongoing Financial Challenges

Yubo International Biotech Limited reported a net loss of $295,026 for the three months ended March 31, 2026, a significant decrease from the net loss of $467,318 recorded in the same period of the previous year. The company did not generate any revenue during this quarter, consistent with the prior year, resulting in zero gross profit. Operating expenses decreased by 38% to $289,274, down from $467,299, primarily due to reduced occupancy costs and lower employee compensation following the early termination of certain leases.

The company's financial position showed a decline in total assets, which fell to $709,872 as of March 31, 2026, compared to $847,095 at the end of 2025. Current liabilities increased to $3,019,451 from $2,791,297, contributing to a negative working capital of $2,421,628. Cash and cash equivalents rose slightly to $10,382 from $8,062, but the company continues to rely on shareholder loans for liquidity. As of March 31, 2026, Yubo had significant payables due to related parties, including $1,242,319 owed to its President, Jun Wang.

Strategically, Yubo has been focusing on restructuring its operations and exploring new sales channels, as indicated by its ongoing market research. The company has not made any significant acquisitions or product launches during this reporting period. However, it has been actively working to improve its operational efficiency and reduce costs, which has contributed to the decrease in operating expenses.

Yubo's corporate structure involves a variable interest entity (VIE) arrangement with Yubo International Biotech (Beijing) Limited, which poses unique risks, particularly regarding compliance with Chinese regulations. The company has not yet established a consistent source of revenue, raising substantial doubt about its ability to continue as a going concern. Management has indicated plans to seek additional capital resources to meet operational needs, including a financial support letter from Jun Wang, which promises continued financial backing for the next 12 months.

Looking ahead, Yubo International Biotech Limited faces challenges in securing additional financing and generating revenue from its operations. The company is committed to identifying new funding sources and improving its market position, but uncertainties regarding regulatory compliance and market conditions in China may impact its future performance. The management's ability to navigate these challenges will be critical for the company's sustainability and growth in the coming quarters.